HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.

Abstract
Global control of tuberculosis (TB), an infectious disease that claims nearly 2 million lives annually, is hindered by the long duration of chemotherapy required for curative treatment. Lack of adherence to this intense treatment regimen leads to poor patient outcomes, development of new or additional drug resistance, and continued spread of M.tb. within communities. Hence, shortening the duration of TB therapy could increase drug adherence and cure in TB patients. Here, we report that addition of the United Stated Food and Drug Administration-approved phosphodiesterase inhibitors (PDE-Is) cilostazol and sildenafil to the standard TB treatment regimen reduces tissue pathology, leads to faster bacterial clearance and shortens the time to lung sterilization by one month, compared to standard treatment alone, in a murine model of TB. Our data suggest that these PDE-Is could be repurposed for use as adjunctive drugs to shorten TB treatment in humans.
AuthorsMamoudou Maiga, Nisheeth Agarwal, Nicole C Ammerman, Radhika Gupta, Haidan Guo, Marama C Maiga, Shichun Lun, William R Bishai
JournalPloS one (PLoS One) Vol. 7 Issue 2 Pg. e30749 ( 2012) ISSN: 1932-6203 [Electronic] United States
PMID22319585 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antitubercular Agents
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Tetrazoles
  • Sildenafil Citrate
  • cilostazol
Topics
  • Animals
  • Antitubercular Agents (therapeutic use)
  • Disease Models, Animal
  • Mice
  • Phosphodiesterase Inhibitors (therapeutic use)
  • Piperazines (therapeutic use)
  • Purines (therapeutic use)
  • Sildenafil Citrate
  • Sulfones (therapeutic use)
  • Tetrazoles (therapeutic use)
  • Time Factors
  • Treatment Outcome
  • Tuberculosis (therapy)
  • United States
  • United States Food and Drug Administration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: